TYK2/JAK1 DUAL INHIBITION PLATFORM
The lead asset in the TYK2/JAK1 dual inhibition platform is BHV-8000 (previously known as TLL-041). BHV-8000 is a first-in-class, oral, brain-penetrant, dual TYK2/JAK1 selective inhibitor. The TYK2 and JAK1 signal transduction pathways mediate highly complementary immune and inflammatory signalling events. Dual inhibition of TYK2 and JAK1 can effectively block Th17 cell generation, Type I IFN signaling, and inflammation.
By reducing the inflammatory impacts of microglia, astrocytes, and infiltrating T-lymphocytes, BHV-8000 breaks the cycle of neuroinflammation.
CNS, central nervous system; JAK, Janus kinase; TYK, tyrosine kinase